The FDA has decided that biosimilar medications must have unique naming features, distinguishing them from brand-name biologics in a move to improve patient safety, according to a STAT news report. 1.
WASHINGTON (Reuters) - The U.S. Food and Drug Administration proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded ...
Hyderabad: Prefixes and suffixes have been banned for all Ayurvedic, Siddha and Unani drugs by the department of AYUSH under the Drugs and Cosmetics Act. This notification was issued despite severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback